Gust Bardy
Hillrom to complete $367M acquisition of Bardy Diagnostics after Delaware judge orders deal to proceed
Hillrom will proceed with its previously announced $367 million acquisition of Seattle startup Bardy Diagnostics after a Delaware judge ordered the deal to close following a dispute over sharp Medicare reimbursement cuts that briefly led Hillrom to try to withdraw.
Hillrom to Buy Bardy Diagnostics for $375M, Deal to Close in Q2 with Possible Milestone Payments
Hillrom will acquire Seattle-based Bardy Diagnostics for $375 million, adding Bardy’s week-long CAM cardiac monitor and related cardiology products to its portfolio; the deal may include future milestone payments and is expected to close in Q2. Bardy, founded in 2013, has about $30 million in annualized revenue, over $20 million in net operating losses, roughly 230 employees, and has raised more than $71 million to date.
Bardy Diagnostics raises $35.5M Series B led by River Cities to scale CAM heart-monitoring platform
Seattle-based Bardy Diagnostics raised $35.5 million in a Series B round led by River Cities Capital Fund to expand sales, monitoring services, and invest in augmented intelligence and visualization for its Carnation Ambulatory Monitor (CAM), a wearable week-long ECG device used on more than 40,000 patients. The company has now raised $71 million total, employs 90 people, and claims the CAM captures clearer heart rhythms than competing monitors.
Organizations
-
Bardy Diagnostics Executive Officer, Director, Promoter 2018, Founder · past